Global Viral Vectors Manufacturing Market

Global Viral Vector Manufacturing Market Overview:

The global Viral Vector Manufacturing market is estimated to reach USD 6.8 million by 2030, growing at a CAGR of 18.7% during the forecast period, 2022-2030. It was valued at USD 1.1 billion in 2022. Viral vectors are sophisticated tools widely used by molecular biologists to deliver genetic material. It is performed inside a living organism or in cell culture. Viral vectors are derived from parental wild-type viruses whose viral genes have been replaced with heterologous genes intended for cell manipulation. It is used as an in-vitro tool to study biomolecules and gene functions and gene therapy, treat genetic disorders, fight cancers, drive tissue regeneration, monitor cell function, and develop vaccines.

Global Viral Vector Manufacturing Market Insights

The major factors are the growing prevalence of target diseases such as diphtheria, measles, poliomyelitis, pertussis, tuberculosis, and tetanus and rising cancer and other infectious diseases. Additionally, the increasing utilization of viral vectors for the development of gene therapy, rising clinical trials, and increasing R&D investments will spur the global viral vector industry in the future periods. Furthermore, the growing public-private funding for viral vectors activities and the development of DNA vaccines are expected to witness remarkable growth of the viral vectors market. The increasing investments in biopharmaceutical production and efficient ability to express the therapeutic genes, and non-pathogenic nature are the factors that are expected to propel the demand for viral vectors over the coming years. Moreover, the upsurge in demand for viral vectors for gene therapy and cell therapy positively impacts the market for viral vectors in the healthcare industry. Furthermore, the rapid expansion in customer base, rise in the extensive R&D activities at the academic and industrial level, and increasing range of biomedical applications are fueling the demand for the viral vectors market. The growing adaptation of viral vectors, including lentiviral vectors, adenoviral vectors, and retroviral vectors, will bolster global viral vectors’ market share. Additionally, the growing geriatric population and increasing medical proposals in the developing world making globally the growth of the viral vectors market.

Growth Driver

Viral vectors are used in gene therapy and the development of viral vaccines, which induce the expression of pathogen protein within host cells. Viral vaccines are much safer as compared to other types of vaccines and prevent sporadic infections by pathogens. Recombinant viruses, including Adenovirus, Lentivirus, and Adeno-associated virus, are currently being used for preclinical and clinical studies, especially in diseases areas such as cancer, rare genetic diseases, central nervous system, and neurodegenerative. In addition, presently, a large number of clinical trials for the production of viral vector vaccines have been conducted against different infectious diseases such as HIV, malaria, influenza viruses, Zika virus, and respiratory syncytial virus. Moreover, Due to the recent Ebola outbreak in West Africa, Two Ebola vaccines using viral vector technology have been used in West Africa. Due to the advantages of large market size, low market concentration, and gradual maturity of technology applications, viral vectors have attracted various enterprises to the layout. However, restrictions are often challenging to achieve. Also, strict regulatory policies, challenges in production, and risks associated with viral vectors will be a restraint to the global viral vectors market.

COVID-19 Impacts Insights

Recently, the outbreak of COVID-19 has vigorously affected the healthcare system of developed and developing countries globally. The growing nervousness regarding the shortage of essential medical life-saving devices and other necessary medical supplies to block the spread of this virus and provide optimum care to the infected also widens. Additionally, Covid-19 is predicted to have a long-term effect on the viral vectors market and manufacturing companies. Moreover, the organizations are putting their efforts to minimize its impending consequences and focus on developing viral vectors vaccines, which is fueling the demand for viral vectors across the globe.

Type Segmental Analysis

Based on the type, the global viral vector manufacturing market is segregated into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The adeno-associated viral vectors segment is estimated to witness the highest growth over the analysis timeframe due to the rise in adoption for gene delivery to treat a variety of human diseases and increase applications in most cell-based gene therapies. The adenoviral vectors will grow significantly due to the capability of supplying both dividing and non-dividing cells with nucleic acids and rising adaptation in gene therapy and vaccines.

Diseases Segmental Analysis

The global viral vector manufacturing market is categorized into cancers, genetic disorders, infectious diseases, and other diseases based on the disease. The cancer segment held a significant market share in 2021 and will gain maximum market revenue by 2030. It is attributable to the rising prevalence of cancer, increasing cancer research, and growing research on viral vector gene therapies. The infectious diseases segment is poised to witness significant growth over the forecast period due to the rising demand for gene therapy and the increasing prevalence of infectious diseases.

Application Segmental Analysis

Based on the application, the global viral vector manufacturing market is classified into gene therapy and Vaccinology. The gene therapy segment is to be the highest revenue share for viral vectors during the forecast period. The growth of the viral vectors is primarily attributed to the rising research activities on viral vector gene therapies and the availability of effective viral vector gene therapies for cancers and rare diseases. Vaccinology will witness a lucrative growth rate in the estimated period due to the rising demand for recombinant vaccines and the increasing prevalence of infectious diseases such as hepatitis B, malaria, etc.

End-User Segmental Analysis

The global viral vector manufacturing market is split up into pharmaceutical and biopharmaceutical companies and research institutes based on the end-user. The pharmaceuticals and biotechnology companies segment will dominate the global viral vector manufacturing market by 2030 due to the continuous introduction of advanced therapies and rising research activities on viral vectors gene therapies, and rising demand for cancer drugs and vaccines. The research institutes accounted for the largest share of the viral vector manufacturing market in 2021 because of the increasing research in molecular biology and increasing research of gene therapy.

Region Segmental Analysis

The global viral vectors market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa by geography. North America is estimated to project considerable growth over 2022-2030. It is owing to advents in technology, the presence of leading industry players offering innovative products, and increasing healthcare expenditure. The Asia Pacific will generate a prominent share of the viral vector manufacturing market by 2030 due to the increasing adoption of gene therapy, continually enhancing healthcare infrastructure in the region, and mounting health care expenditures in developing countries such as India and China.

Competitor Analysis

Companies such as Merck, CGT Catapult, uniQure, Spark Therapeutics, Lonza, Oxford BioMedica, Cobra Biologics, and FUJIFILM Diosynth Biotechnologies are the key players in the global viral vector manufacturing market.

Key Stakeholders

• Market research and consulting firms
• Industry associations
• Global viral-based products manufacturing firm
• Research organizations and consulting companies
• Organizations, associations, and alliances related to viral vector manufacturing
• Regulatory bodies
• Suppliers
• Retailers

The objective of the research

• Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
• Product analysis involves examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
• Market Trend and Economic Factors Analysis helps assess potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
• Market Segmental Analysis defines an in-depth scenario of the target market by grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics.
• The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs, wants, and cultural characteristics that can specifically target.

Market Modelling

 By Type

• Retroviral Vectors
• Adenoviral Vectors
• Adeno-Associated Viral Vectors
• Other Viral Vectors

 By Disease

• Cancers
• Genetic Disorders
• Infectious diseases
• Other Diseases

By Application

• Gene Therapy
• Vaccinology

By End-User

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

UK Childcare Software Market Report

Connected Car Market

Parenteral Products Packaging Market

Cold Chain Monitoring Market

Global 3D Food Printing Market

Vibrating Microtome Market

Whooping Cough Treatment Market

Feed Pusher Market

Aluminum Extrusion Market